Article info
PDFEBM analysis
FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps
- Correspondence to Dr John G Rizk, University of Maryland Baltimore, Baltimore, Maryland, USA; john.rizk{at}umaryland.edu
Citation
FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps
Publication history
- Accepted April 2, 2022
- First published April 21, 2022.
Online issue publication
May 05, 2023
Article Versions
- Previous version (23 March 2023).
- Previous version (28 April 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.